BioAge Labs, Inc.
No SEC Form 4 filings for $BIOA in the last 30 days.
BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bioa-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic
BioAge Labs (BIOA) and Monte Rosa Therapeutics (GLUE) fell after Novo Nordisk (NVO) reported its late-stage ZEUS trial for ziltivekimab failed to reduce heart attack, stroke, and related deaths despite lowering inflammation markers. BIOA dropped 64% and GLUE about 27%. Analysts cut BIOA and GLUE price targets while keeping Buy ratings.
BioAge Labs shares dropped about 59.6% after Novo Nordisk reported its Phase 3 ZEUS trial of ziltivekimab failed to reduce major adverse cardiovascular events versus placebo in 6,300+ patients, with a hazard ratio of 0.99. The result challenged the cardiovascular inflammation approach relevant to BioAge’s BGE-102 (QUELL-CV Phase 2).
Over the past 7 days, alphai's AI scored 1 news story mentioning BIOA (BioAge Labs, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent BIOA coverage spans market movers, technology and earnings.
Near-term trading focus is likely on QUELL-CV progress and the implied probability of achieving hsCRP endpoint support for BGE-102 dose selection.
High negative read-through from a peer’s failed late-stage trial, amplified by sharp selloff and analyst PT cuts.
The ZEUS Phase 3 failure directly challenges the inflammatory-cardiovascular hypothesis that BioAge’s pipeline is positioned to benefit from.
The move is consistent with a risk-off tape reaction, but the article lacks the underlying reason.
Higher Leqembi sales translate into higher BioArctic royalties, supporting near-term revenue visibility for the royalty stream.
alphai scores every news story that mentions BIOA with an AI model for sentiment and relevance, and aggregates insider trades from BioAge Labs, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bioa-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic
6 min readBioAge Labs (BIOA) and Monte Rosa Therapeutics (GLUE) fell after Novo Nordisk (NVO) reported its late-stage ZEUS trial for ziltivekimab failed to reduce heart attack, stroke, and related deaths despite lowering inflammation markers. BIOA dropped 64% and GLUE about 27%. Analysts cut BIOA and GLUE price targets while keeping Buy ratings.
4 min readBioAge Labs shares dropped about 59.6% after Novo Nordisk reported its Phase 3 ZEUS trial of ziltivekimab failed to reduce major adverse cardiovascular events versus placebo in 6,300+ patients, with a hazard ratio of 0.99. The result challenged the cardiovascular inflammation approach relevant to BioAge’s BGE-102 (QUELL-CV Phase 2).
4 min readRTTNews reports notable premarket moves ahead of Friday’s open, highlighting gainers including REPL (+131% to $12.49), AXT (+34% to $62.94), COHU (+24% to $57.70) and NWL (+19% to $6.11). Losers include BIOA (-53% to $11.64), DFNS (-49% to $43.50), GLUE (-29% to $16.00) and PN (-27% to $17.20).
2 min readBioArctic AB said its partner Eisai reported preliminary Q2 2026 global Leqembi sales of JPY 29.3 billion. BioArctic’s royalty is SEK 179 million, about 10% higher than in Q2 2025. Excluding a Q2 2025 China stockpiling effect of about JPY 5.3 billion, royalty revenues rose about 43% year over year. BioArctic’s Q2 report is due Aug 26, 2026.
3 min readHitGen Inc. (SSE:688222) said its partner BioAge Labs (NASDAQ:BIOA) dosed the first participant in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102, an oral NLRP3 inhibitor for cardiovascular risk reduction. BioAge expects topline Phase 2 data in H2 2026. Phase 1 reportedly showed hsCRP reductions on once-daily dosing.
2 min readBioArctic AB said Eisai received FDA approval for a supplemental BLA allowing once-weekly subcutaneous lecanemab-irmb (Leqembi Iqlik) as a starting dose for early Alzheimer’s. The regimen is 500 mg weekly (two 250 mg injections). US launch is planned for late Aug 2026. Patients can use SC or IV throughout treatment.
4 min readBarton Shane (Principal Accounting Officer) sold 62,566 shares of BioAge Labs, Inc. (BIOA) at an average of $25.20 ($25.19–$25.21, $1.58M total) across 2 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
2 min readBioArctic AB said Eisai will present new clinical and real-world evidence on lecanemab (Leqembi) at the AAIC conference in London July 12-15, including data on subcutaneous dosing, long-term use, maintenance dosing, and at-home administration. BioArctic will also participate in a plenary session on Alzheimer’s pathology prevalence. The release notes regulatory updates, including an FDA sBLA PDUFA date of Aug. 24, 2026.
3 min readBioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001709941 false 0001709941 dei:FormerAddressMember 2026-06-10 2026-06-10 0001709941 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Da
2 min read
